Angelini Pharma: the global growth of an italian healthcare champion

Angelini Pharma is a leading Italian pharmaceutical company with direct operations in 20 countries and a commercial presence in more than 70 markets worldwide. 

In 2026, CDP Equity approved a €1 billion capital increase investment, acquiring a 23.5% stake in the company. The transaction supports the acquisition of the U.S.-based company Catalyst Pharmaceuticals and marks a significant step in Angelini Pharma’s transformation from an Italian and European pharmaceutical company into a global player in brain health and rare diseases, while keeping Italy at the heart of its manufacturing operations and scientific research. 

The investment helps strengthen a strategic value chain with strong growth potential by supporting the international expansion of a national champion and backing a €1.3 billion research and development investment plan. It also aims to attract highly skilled talent, enhance Italy’s strategic autonomy and reinforce the competitiveness of the country’s pharmaceutical industry.

 

Learn more 

LinkedIn post by the CEO of CDP Equity